Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Abstract The antibody‐drug conjugate (ADC) tisotumab vedotin (TV) received accelerated approval from the US Food and Drug Administration for treatment of adults with recurrent or metastatic cervical cancer (r/mCC) with disease progression on or after chemotherapy. A population pharmacokinetic (PK) m...

Full description

Bibliographic Details
Main Authors: Chaitali Passey, Jenna Voellinger, Leonid Gibiansky, Rudy Gunawan, Leonardo Nicacio, Ibrahima Soumaoro, William D. Hanley, Helen Winter, Manish Gupta
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.13007

Internet

https://doi.org/10.1002/psp4.13007

Similar Items